| Cardiac condition | Types | Expression | Note |
| Normal fetal heart
| miR-21, 29a, 129, 210 , 211,320, 423, let-7c | Upregulation
| Decreased Expression leads to hypoplastic ventricles , pericardial edema |
| Cardiac Development
| miR-1. miR-133a
| Upregulation during early development
| miR-1 overexpression leads to dysregulation of cardiac myocyte proliferation, myoblast differentiation, VSD. lossmiR-1, miR-133 result in VSD, Cardiac chamber dilation. |
| Cardiac remodeling | miR-1, miR-133 miR-21, 195 208, 214 | Downregulation Upregulation | A potential biomarker
|
| Ventricular Arrhythmia | miR-1 | Upregulation | Anti-miR-1, a potential therapy |
| Atrial Fibrillation | miR-328 miR-1 | Upregulation Downregulation | Anti-miR-328, a potential therapy
|
| Hypertension | miR-155, 181, 663 miR-132, 212, 20a | Downregulation Upregulation | Potential biomarker
|
| Heart Failure | miR-1, 21, 22 23, 29, 92b, 130, 195, 199, 210, 320a 423-5p, 499, 622 | Upregulation | miR-425-5p is strongly correlated with clinical diagnosis of heart failure |
| Myocardial Infarction | miR-1, 15, 133a, 208b, 499 miR-24 | Upregulated Downregulated | miR-499 is inclusive to cardiac muscle, a potential biomarker |
| Atherosclerosis | miR-33, 122, 370 | Upregulated | Anti miR-33 is atheroprotective, a potential therapy |
| miR-126, 145, 155 | Downregulated | miR-126, 145, 155 are atheroprotective function, a potential therapy | |
| Congenital heart disease |
|
|
|
| VSD | miR-181-c miR-1 | Upregulated Downregulated | All of these findings will lead to early detection of congenital heart disease and possible therapeutic intervention |
| Tatralogy of Fallot | miR-421 miR-940 | Upregulated Downregulated |
|
| Bicuspid Aortic valve | miR-26a, 30b, 141, 195 | Downregulated |
|